226 filings
Page 6 of 12
6-K
33f7l7kcb7hpq 714zc
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
7smx6yr
28 Jan 21
ObsEva to Increase Issued Share Capital by Creating
4:26pm
6-K/A
yirdggx1
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
049g2
13 Jan 21
Current report (foreign)
4:00pm
6-K
ceb n7ugn6w4is4py
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K/A
zkcbwbuwz830lu k56d
4 Jan 21
Current report (foreign) (amended)
6:36am
6-K
blm19 3n6t7ss2v
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
zsmefu6six 1vxp7q
10 Dec 20
Current report (foreign)
6:03am
6-K
k06zs5102q7q1xzp
24 Nov 20
Current report (foreign)
6:03am
6-K
mvtg9fg3
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
vod86tjdcj4dy
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
4dsbn
5 Nov 20
Index to Unaudited Condensed Consolidated Financial Statements
6:02am
S-8
ycftq8p x0gg
13 Oct 20
Registration of securities for employees
4:16pm
6-K
9v86rs 83coy5vduw
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
evcll1vx
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
b3jbn drqxfr9qc
14 Aug 20
Current report (foreign)
4:24pm
6-K
tkpppx9ls0vdkoo3yb
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
xvxbmvo
7 Jul 20
Current report (foreign)
3:39pm
6-K
k67ykfwgzgude0r4
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
ndupmxr82057anywvj
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am